Arvinas, Inc. Stock News

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Gr...

– Secured the first-ever regulatory approval of a PROTAC (a type of  heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating...

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of ...

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson...